ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Cogent Biosciences Inc

Cogent Biosciences Inc (COGT)

7,64
-0,55
(-6,72%)
Geschlossen 19 Dezember 10:00PM
7,64
0,00
( 0,00% )
Vor Marktöffnung: 10:00AM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
7,64
Gebot
6,20
Fragen
12,00
Volumen
-
0,00 Tagesbereich 0,00
4,28 52-Wochen-Bereich 12,61
Marktkapitalisierung
Handelsende
7,64
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
1.366.687
Ausgegebene Aktien
110.461.729
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,35
Gewinn pro Aktie (EPS)
-1,74
Erlöse
-
Nettogewinn
-192,41M

Über Cogent Biosciences Inc

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibit... Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Dover, Delaware, USA
Gegründet
-
Cogent Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker COGT. The last closing price for Cogent Biosciences was US$7,64. Over the last year, Cogent Biosciences shares have traded in a share price range of US$ 4,28 to US$ 12,61.

Cogent Biosciences currently has 110.461.729 shares in issue. The market capitalisation of Cogent Biosciences is US$843,93 million. Cogent Biosciences has a price to earnings ratio (PE ratio) of -1.35.

COGT Neueste Nachrichten

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS                   89% of patients had >50% decrease in serum...

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months...

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Top-line results from registration-directed SUMMIT, PEAK and APEX trials expected in 2025 Phase 1 trial initiated for CGT-4859, a reversible, potent, selective, FGFR2 inhibitor SUMMIT and APEX...

Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting

WALTHAM, Mass. and BOULDER, Colo., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...

Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics

     Preclinical data highlight company’s fourth discovery stage program, a novel potent and selective KRAS(ON) inhibitor Updated preclinical data from CGT6297, Cogent’s H1047R mutant-selective...

Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis

413 patients enrolled in PEAK Phase 3 GIST trial, exceeding enrollment target; top-line results expected by end of 2025 PEAK interim futility analysis completed with no changes to study...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1.62-17.4946004329.269.267.29517755758.17529891CS
4-1.48-16.22807017549.1210.54517.29517000989.0515418CS
12-3.33-30.35551504110.9712.617.29513666879.99483765CS
26-0.88-10.32863849778.5212.617.29511382689.83837474CS
523.0967.91208791214.5512.614.2814510698.08545706CS
156-0.62-7.506053268778.2618.073.6711786649.16365184CS
2605.44247.2727272732.218.072.29443189.09005281CS

COGT - Frequently Asked Questions (FAQ)

What is the current Cogent Biosciences share price?
The current share price of Cogent Biosciences is US$ 7,64
How many Cogent Biosciences shares are in issue?
Cogent Biosciences has 110.461.729 shares in issue
What is the market cap of Cogent Biosciences?
The market capitalisation of Cogent Biosciences is USD 843,93M
What is the 1 year trading range for Cogent Biosciences share price?
Cogent Biosciences has traded in the range of US$ 4,28 to US$ 12,61 during the past year
What is the PE ratio of Cogent Biosciences?
The price to earnings ratio of Cogent Biosciences is -1,35
What is the reporting currency for Cogent Biosciences?
Cogent Biosciences reports financial results in USD
What is the latest annual profit for Cogent Biosciences?
The latest annual profit of Cogent Biosciences is USD -192,41M
What is the registered address of Cogent Biosciences?
The registered address for Cogent Biosciences is 838 WALKER ROAD, SUITE 21-2, KENT, DOVER, DELAWARE, 19904
What is the Cogent Biosciences website address?
The website address for Cogent Biosciences is www.unumrx.com
Which industry sector does Cogent Biosciences operate in?
Cogent Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
XHGXChange TED Inc
US$ 2,67
(254,11%)
3,6M
CURRCurrenc Group Inc
US$ 6,50
(225,00%)
4,35M
APCXAppTech Payments Corporation
US$ 1,06
(178,22%)
36,17M
MESOMesoblast Limited
US$ 17,83
(45,55%)
79,81k
XYLOXylo Technology Ltd
US$ 4,45
(41,27%)
2
LITMSnow Lake Resources Ltd
US$ 0,47
(-42,65%)
2,35M
AEMDAethlon Medical Inc
US$ 0,4254
(-35,60%)
554,45k
MULLGranite Shares 2x Long MU Daily ETF
US$ 15,27
(-30,18%)
13,03k
MUUDirexion Daily MU Bull 2X Shares
US$ 17,50
(-28,69%)
50,62k
WAITop KingWin Ltd
US$ 0,2303
(-27,58%)
1
APCXAppTech Payments Corporation
US$ 1,06
(178,22%)
36,17M
CURRCurrenc Group Inc
US$ 6,50
(225,00%)
4,35M
XHGXChange TED Inc
US$ 2,66
(252,79%)
3,6M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,387
(6,09%)
3,01M
SGMOSangamo Therapeutics Inc
US$ 2,65
(12,77%)
3M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock